These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Impairment of renal function after intravenous immunoglobulin. Soares SM; Sethi S Nephrol Dial Transplant; 2006 Mar; 21(3):816-7. PubMed ID: 16399766 [No Abstract] [Full Text] [Related]
7. Chronic inflammatory demyelinating polyneuropathy in a diabetic patient: deterioration after intravenous immunoglobulins treatment and favorable response to steroid treatment. Pedersen K; Pandolfo M; Mavroudakis N Acta Neurol Belg; 2007 Mar; 107(1):14-7. PubMed ID: 17569228 [TBL] [Abstract][Full Text] [Related]
8. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Lin CS; Krishnan AV; Park SB; Kiernan MC Arch Neurol; 2011 Jul; 68(7):862-9. PubMed ID: 21747028 [TBL] [Abstract][Full Text] [Related]
9. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749 [TBL] [Abstract][Full Text] [Related]
10. What is the best initial treatment for childhood chronic inflammatory demyelinating polyneuropathy: corticosteroids or intravenous immunoglobulin? Sladky JT Muscle Nerve; 2008 Dec; 38(6):1638-43. PubMed ID: 19016535 [No Abstract] [Full Text] [Related]
12. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. Cocito D; Ciaramitaro P; Isoardo G; Barbero P; Migliaretti G; Pipieri A; Proto G; Quadri R; Bergamasco B; Durelli L J Neurol; 2002 Jun; 249(6):719-22. PubMed ID: 12111305 [TBL] [Abstract][Full Text] [Related]
13. Improvement of axonal function in patients with chronic inflammatory demyelinating polyneuropathy after intravenous immunoglobulin therapy. Hughes RA; Mills K Arch Neurol; 2011 Jul; 68(7):844-6. PubMed ID: 21747026 [No Abstract] [Full Text] [Related]
14. Corticosteroids can help distinguish between Guillain-Barré syndrome and first attack of chronic inflammatory demyelinating neuropathy: an illustrative case report. Alexander KJ; Alshubaili AF; Santhamoorthy P; Sharafuddin KM Med Princ Pract; 2008; 17(5):422-4. PubMed ID: 18685286 [TBL] [Abstract][Full Text] [Related]
16. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease. Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654 [TBL] [Abstract][Full Text] [Related]
18. Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review. Abbas A; Rajabally YA Curr Drug Saf; 2019; 14(1):3-13. PubMed ID: 30332974 [TBL] [Abstract][Full Text] [Related]
19. Individual patients who experienced both Guillain-Barré syndrome and CIDP. Kuitwaard K; van der Pol WL; Ruts L; van Doorn PA J Peripher Nerv Syst; 2009 Mar; 14(1):66-8. PubMed ID: 19335542 [No Abstract] [Full Text] [Related]
20. Chronic inflammatory demyelinating polyneuropathy in a patient with hyperIgEaemia. Kimura A; Yoshino H; Yuasa T J Neurol Sci; 2005 Apr; 231(1-2):89-93. PubMed ID: 15792827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]